- Home
- / Dare Bioscience
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Dare Bioscience financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4
2024-10-29
Market Capitalization
$33.8 M
2024-10-29
Revenue
$1 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 03, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 80.0K | 766.0K | 10.0M | 2.8M | 9.8K | 1.0M | ||||||
| Cost of goods sold | 295.8K | |||||||||||
| Gross profit | 734.4K | |||||||||||
| Gross profit margin, % | 71.3% | |||||||||||
| General and administrative expense | 8.6M | 11.2M | 10.4M | 2.7M | 4.7M | 5.3M | 6.5M | 8.4M | 11.2M | 12.1M | 9.2M | 8.8M |
| Operating expense total | 20.4M | 37.2M | 37.9M | 3.7M | 11.1M | 13.8M | 27.3M | 41.3M | 33.6M | 23.4M | 14.3M | |
| EBIT | (11.2M) | (16.9M) | (14.3M) | (27.4M) | (39.1M) | (31.4M) | (30.9M) | (23.5M) | (13.6M) | |||
| EBIT margin, % | -313.9% | -1101.9% | -239692.2% | -1315.5% | ||||||||
| Interest income | 9.0K | 10.0K | 86.0K | |||||||||
| Interest expense | 2.4M | 2.2M | ||||||||||
| Pre tax profit | (11.5M) | (16.8M) | (14.3M) | (27.4M) | (38.7M) | (30.9M) | (30.2M) | (4.1M) | (13.5M) | |||
| Income tax expense | 3.2K | |||||||||||
| Net Income | (23.3M) | (39.6M) | (39.3M) | (11.5M) | (16.7M) | (14.3M) | (27.4M) | (38.7M) | (30.9M) | (30.2M) | (4.1M) | (13.4M) |
| EPS | (0.4) | (0.3) | (0.5) | (1.2) |